Chang‐Min Choi
YOU?
Author Swipe
View article: Temporal changes in tongue color during immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer: a prospective observational study using digital tongue diagnosis
Temporal changes in tongue color during immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer: a prospective observational study using digital tongue diagnosis Open
Background Tongue diagnosis (TD), a key component of traditional East Asian medicine, employs a unique pattern-based diagnostic system. Digital TD enables quantitative assessment of tongue characteristics, like body and coating color, enha…
View article: Extended Follow‐Up Analysis of First‐Line Atezolizumab in Extensive‐Stage Small Cell Lung Cancer: A Real‐World Multicenter Prospective Cohort Study
Extended Follow‐Up Analysis of First‐Line Atezolizumab in Extensive‐Stage Small Cell Lung Cancer: A Real‐World Multicenter Prospective Cohort Study Open
Background We previously reported the short‐term real‐world effectiveness and safety of first‐line atezolizumab combined with chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC). This study provides an updated an…
View article: XP-STM: A Cross-Platform Sentiment Transferability model for Negative Public Sentiment Identification and Mitigation
XP-STM: A Cross-Platform Sentiment Transferability model for Negative Public Sentiment Identification and Mitigation Open
View article: Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients
Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients Open
Background Second‐generation anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and brigatinib, are widely used in patients with ALK‐positive non‐small cell lung cancer (NSCLC) who develop resistance or progress on crizotinib…
View article: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study
Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study Open
The trial was registered with the Clinical Research Information Service ( https://cris.nih.go.kr/cris ; identifier number: KCT0006689) in October 2021.
View article: Effect of needle aspiration for treatment of moderate to severe non-tension pneumothorax after transthoracic needle biopsy
Effect of needle aspiration for treatment of moderate to severe non-tension pneumothorax after transthoracic needle biopsy Open
Needle aspiration is a safe and effective procedure for the treatment of moderate to severe non-tension pneumothorax following TTNB. It may reduce the need for chest tube insertion, shorten hospitalization duration, and decrease procedure-…
View article: Comparison of metastasis and treatment patterns among different histopathologic types of lung cancer: analysis of 6 years of nationwide lung cancer cohort data in Korea
Comparison of metastasis and treatment patterns among different histopathologic types of lung cancer: analysis of 6 years of nationwide lung cancer cohort data in Korea Open
Understanding metastasis patterns and treatment options specific to each lung cancer histologic type is essential for improving treatment strategies.
View article: Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation Open
Introduction The provision of treatment for epidermal growth factor receptor (EGFR)‐mutated nonsmall cell lung cancer (NSCLC) patients has increased in Korea. However, multicenter studies on the clinicopathologic dataset and treatment outc…
View article: Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment
Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment Open
Non-small cell lung cancer (NSCLC) is histologically classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC). However, some tumors are histologically ambiguous and other pathophysiological features or microenviro…
View article: Utility of chronic obstructive pulmonary disease assessment test in perioperative assessment of patients with mild to moderate chronic obstructive pulmonary disease
Utility of chronic obstructive pulmonary disease assessment test in perioperative assessment of patients with mild to moderate chronic obstructive pulmonary disease Open
CAT scores are valuable for evaluating patients with mild to moderate COPD before lung resection surgery, reliably predicting PPCs.
View article: Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data
Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data Open
Purpose Recent development in perioperative treatment of resectable non–small cell lung cancer (NSCLC) have changed the landscape of early lung cancer management. The ADAURA trial has demonstrated the efficacy of adjuvant osimertinib treat…
View article: Optimal approach for diagnosing peripheral lung nodules by combining electromagnetic navigation bronchoscopy and radial probe endobronchial ultrasound
Optimal approach for diagnosing peripheral lung nodules by combining electromagnetic navigation bronchoscopy and radial probe endobronchial ultrasound Open
Introduction Electromagnetic navigation bronchoscopy (ENB) and radial probe endobronchial ultrasound (RP‐EBUS) are essential bronchoscopic procedures for diagnosing peripheral lung lesions. Despite their individual advantages, the optimal …
View article: A prospective, open-label, randomized clinical trial to evaluate the efficacy and safety of remimazolam in patients undergoing EBUS-TBNA: REST trial design
A prospective, open-label, randomized clinical trial to evaluate the efficacy and safety of remimazolam in patients undergoing EBUS-TBNA: REST trial design Open
Background Remimazolam is safe and effective for moderate sedation during flexible bronchoscopy, but its safety and efficacy during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) remains undetermined. The REST…
View article: Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer
Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer Open
Background: The use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer is increasing. Despite ongoing studies to predict the efficacy of ICIs, its use in clinical practice remains difficult. Thus, we aimed to disc…
View article: Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease
Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease Open
View article: 22P Evaluation of co-mutation in EGFR-mutant non-small cell lung cancer by next generation sequencing (NGS): Retrospective cohort study in South Korea
22P Evaluation of co-mutation in EGFR-mutant non-small cell lung cancer by next generation sequencing (NGS): Retrospective cohort study in South Korea Open
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard First-line treatments for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, despite optimal therapies, not all patients have …
View article: Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study Open
Background Choosing treatments for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with osimertinib resistance is challenging. We evaluated the safety and efficacy of SNK01 (autologous natural ki…
View article: Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Open
Real-world data on the use and outcomes of crizotinib in ROS1-rearranged non-small-cell lung cancer (NSCLC) are limited. This study aims to analyze the real-world efficacy of crizotinib in South Korea and explore the utilization of liquid …
View article: In-hospital real-time prediction of COVID-19 severity regardless of disease phase using electronic health records
In-hospital real-time prediction of COVID-19 severity regardless of disease phase using electronic health records Open
Coronavirus disease 2019 (COVID-19) has strained healthcare systems worldwide. Predicting COVID-19 severity could optimize resource allocation, like oxygen devices and intensive care. If machine learning model could forecast the severity o…
View article: Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors Open
Purpose This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.Materials…
View article: Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data Open
Purpose This study aimed to assess the real-world clinical outcomes of consolidative durvalumab in patients with unresectable locally advanced non–small cell lung cancer (LA-NSCLC) and to explore the role of radiotherapy in the era of immu…
View article: Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea Open
Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK‐positive NSCLC. This study aimed to analyze the real…
View article: PPIB/Cyclophilin B expression associates with tumor progression and unfavorable survival in patients with pulmonary adenocarcinoma
PPIB/Cyclophilin B expression associates with tumor progression and unfavorable survival in patients with pulmonary adenocarcinoma Open
Cyclophilin B (CypB), encoded by peptidylprolyl isomerase B (PPIB), is involved in cellular transcriptional regulation, immune responses, chemotaxis, and proliferation. Recent studies have shown that PPIB/CypB is associated with tum…
View article: Correction: Conditional diagnostic accuracy according to inflammation status and age for diagnosing tuberculous effusion
Correction: Conditional diagnostic accuracy according to inflammation status and age for diagnosing tuberculous effusion Open
View article: Revolutionizing Non–Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma
Revolutionizing Non–Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma Open
Purpose Circulating cell-free DNA (cfDNA) has great potential in clinical oncology. The prognostic and predictive values of cfDNA in non–small cell lung cancer (NSCLC) have been reported, with epidermal growth factor receptor (EGFR)…
View article: The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study Open
Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we i…
View article: Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study Open
Purpose The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. Thi…
View article: Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data Open
Afatinib was effective in Korean patients with EGFR mutation-positive NSCLC with median OS over 4 years. The presence of baseline brain metastases and/or uncommon EGFR mutations were associated with reduced survival. In the a…
View article: EP07.04-18 Factors Associated with Postoperative Recurrence in Early NSCLC with EGFR Mutation: Analysis of Korean National Population Data
EP07.04-18 Factors Associated with Postoperative Recurrence in Early NSCLC with EGFR Mutation: Analysis of Korean National Population Data Open
View article: P1.28-12 Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
P1.28-12 Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy Open